The Markey Cancer Center (MCC) is directed by B. Mark Evers, MD with the assistance of nationally recognized leaders in cancer research, prevention and clinical care. Senior Leadership of the MCC includes: Susanne M. Arnold, MD (Associate Director for Clinical Translation);David M. Gosky, MA, MBA (Associate Director for Administration);Daret St. Clair, PhD (Associate Director for Basic Research) and Thomas Tucker, PhD, MPH (Associate Director for Cancer Prevention and Control). This highly experienced Senior Leadership team works together to ensure consistency in the shared vision and goals of the MCC;to develop synergistic and highly collaborative interactions among the basic, translational and clinical components of the Center;to plan proactive approaches to the development of the research base and resources;to effectively leverage all available resources at the University of Kentucky and at the state and national levels;to engage in community outreach and philanthropy;and to oversee all activities of the MCC. This Senior Leadership team meets several times a month in some capacity (i.e., in the context of various MCC Board/Committee/Council meetings, one-on-one with the Director, and bi-weekly as a Director's Council). They provide critical advice and recommendations to the Director based on those interactions. All final authority for decisions on behalf of the MCC resides with the Director.
Support is requested for several members of the MCC Senior Leadership team who provide advice and recommendations to the Director regarding the strategic planning and evaluation of the Center's efforts.
|Wei, Xiaowei; Xu, Yong; Xu, Fang Fang et al. (2017) RelB Expression Determines the Differential Effects of Ascorbic Acid in Normal and Cancer Cells. Cancer Res 77:1345-1356|
|Cui, Jiajun; Xu, Wenhua; Chen, Jian et al. (2017) M2 polarization of macrophages facilitates arsenic-induced cell transformation of lung epithelial cells. Oncotarget 8:21398-21409|
|Wu, Yadi; Wang, Yu; Lin, Yiwei et al. (2017) Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation. Nat Commun 8:14228|
|Wise, James T F; Wang, Lei; Zhang, Zhuo et al. (2017) The 9th Conference on Metal Toxicity and Carcinogenesis: The conference overview. Toxicol Appl Pharmacol 331:1-5|
|Carpenter, Brittany L; Liu, Jinpeng; Qi, Lei et al. (2017) Integrin ?6?4 Upregulates Amphiregulin and Epiregulin through Base Excision Repair-Mediated DNA Demethylation and Promotes Genome-wide DNA Hypomethylation. Sci Rep 7:6174|
|Jarrett, Stuart G; D'Orazio, John A (2017) Hormonal Regulation of the Repair of UV Photoproducts in Melanocytes by the Melanocortin Signaling Axis. Photochem Photobiol 93:245-258|
|Li, Liqing; Li, Xiang; Qi, Lei et al. (2017) The role of talin2 in breast cancer tumorigenesis and metastasis. Oncotarget 8:106876-106887|
|Kenlan, Dasha E; Rychahou, Piotr; Sviripa, Vitaliy M et al. (2017) Fluorinated N,N'-Diarylureas As Novel Therapeutic Agents Against Cancer Stem Cells. Mol Cancer Ther 16:831-837|
|Son, Young-Ok; Pratheeshkumar, Poyil; Divya, Sasidharan Padmaja et al. (2017) Nuclear factor erythroid 2-related factor 2 enhances carcinogenesis by suppressing apoptosis and promoting autophagy in nickel-transformed cells. J Biol Chem 292:8315-8330|
|Arnold, Susanne M; Chansky, Kari; Leggas, Markos et al. (2017) Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553). Invest New Drugs 35:608-615|
Showing the most recent 10 out of 281 publications